RARA CRAFT DATABASE for FDA Medical Devices
De NovoDEN250057

FDA DEVICE FACTS

PCWP Analysis Software

Cardiosense, Inc.

FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。

PCCP: Authorized
DECISION DATEMay 22, 2026PRODUCT CODESIF

Indications for use

PCWP Analysis Software is intended to noninvasively estimate pulmonary capillary wedge pressure (PCWP) and identify patients with a PCWP above or below 18mmHg, for patients diagnosed with heart failure with reduced ejection fraction (HFrEF) and New York Heart Association (NYHA) Functional Class II, III, IV symptoms. The hemodynamic data will be used by qualified healthcare professionals in conjunction with other standard of care parameters to evaluate heart failure patients. The results of PCWP Analysis Software are intended to be used under the supervision of a qualified healthcare professional in conjunction with the patient's clinical history, symptoms, and other diagnostic tests, as well as the qualified healthcare professional's judgment. Patient management decisions should not be made solely on the results of the PCWP Analysis Software. The device is only for prescription use.

See the full product information製品情報をすべて見るには

Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。

Start free 7-day access7日間無料で利用するLog inログイン

OFFICIAL FDA SOURCES

FDA Record and Public Document Status

Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。

Information reviewed:情報の確認日: July 28, 2026